Modality
Vaccine
MOA
BCMA ADC
Target
CDK2
Pathway
Amyloid
Wilms
Development Pipeline
Preclinical
~Sep 2013
→ ~Dec 2014
Phase 1
~Mar 2015
→ ~Jun 2016
Phase 2
~Sep 2016
→ ~Dec 2017
Phase 3
~Mar 2018
→ ~Jun 2019
NDA/BLA
Sep 2019
→ Nov 2025
NDA/BLACurrent
NCT03371989
29 pts·Wilms
2019-09→2025-11·Active
29 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-274mo agoPh3 Readout· Wilms
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
NDA/BLA
Active
Catalysts
Ph3 Readout
2025-11-27 · 4mo ago
Wilms
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03371989 | NDA/BLA | Wilms | Active | 29 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A |